MAGEA4
Melanoma-associated antigen 4
As of the edition of 20 October 2026, MAGEA4 (melanoma-associated antigen 4, UniProt P43358) has 2 drugs tested at it and 3 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43358
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 12
- Registered trials of its drugs
- 1
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| RO7444973 | Stopped | Phase 1 | none listed |
| Afamitresgene autoleucel | Marketed | No phase stated | Ends 2036 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Undetermined | 1 |
| Total on the list | 3 |
The other 1 company at MAGEA4
In the product3 companies in all; 1 is not named here, and no score is.
See the 3 companies at MAGEA4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.